logo
Leaf it to science: SA researchers uncover the hidden power of cannabis leaves

Leaf it to science: SA researchers uncover the hidden power of cannabis leaves

News244 days ago
When it comes to cannabis, the spotlight often shines on the buds. But what if the overlooked leaves hold untapped potential for pharmaceuticals?
For most cannabis growers, producing top-quality buds is the ultimate goal. Vibrant colours, frosty trichomes, and a strong, pleasant smell are key signs of a high-quality strain, and growers focus closely on these features.
Given the diverse applications of cannabis for both recreational and medicinal purposes, it's unsurprising that significant emphasis is placed on cultivating high-quality strains.
On the other hand, cannabis plants' leaves are often seen as unhelpful and are believed to drain nutrients from the buds. Consequently, growers frequently remove the leaves to prevent the transfer of energy away from the flowers.
A groundbreaking discovery: Flavoalkaloids
However, researchers from Stellenbosch University (SU) discovered that these leaves may be more valuable than previously thought. For the first time, they identified a rare class of phenolics, flavoalkaloids, in cannabis leaves.
Phenolic compounds, like flavonoids, are natural chemicals found in fruits and plants.
Image by Magriet Muller.
They are known for their health-boosting antioxidant and anti-inflammatory effects and are highly sought after in the pharmaceutical industry due to their antioxidant, anti-inflammatory, and anti-carcinogenic properties.
The researchers studied three strains of cannabis grown in South Africa and identified 79 phenolic compounds, 25 of which were discovered for the first time in cannabis.
Among these were 16 flavoalkaloids, primarily found in the leaves of one specific strain.
Challenges in analysing plant phenolics
Wiida Fourie-Basson
Dr Magriet Muller, an analytical chemist at SU's LC-MS laboratory, and the study's lead author, highlighted the challenges of analysing plant phenolics due to their low concentrations and structural diversity.
'Most plants contain highly complex mixtures of phenolic compounds, and while flavonoids are commonly found across the plant kingdom, flavoalkaloids are exceptionally rare in nature,' she explained.
'We know that cannabis is extremely complex – it contains more than 750 metabolites – but we did not expect such high variation in phenolic profiles between only three strains, nor to detect so many compounds for the first time in the species. Especially the first evidence of flavoalkaloids in cannabis was very exciting.'
A bright future for pharmaceuticals
While people have long used cannabis leaves for eating, making concentrates, and crafting homemade salves, the discovery of these flavonoids marks a breakthrough.
This discovery has the potential to revolutionise pharmaceutical treatments, holding the potential for things like plant-based alternatives to synthetic medicines for combating inflammation, preventing cancer, or improving overall well-being.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Young Adults Increasingly Choose Weed Drinks Over Alcohol, Poll Shows
Young Adults Increasingly Choose Weed Drinks Over Alcohol, Poll Shows

Forbes

time6 hours ago

  • Forbes

Young Adults Increasingly Choose Weed Drinks Over Alcohol, Poll Shows

American young adults are increasingly choosing cannabis-infused beverages over alcohol, according to the results of recent survey. The poll found that one out of three millennial and Gen Z adults choose weed drinks over alcoholic beverages at after-work functions such as happy hours, Marijuana Moment reported this week. The survey was conducted by Drug Rehab USA to gauge the recreational choices of 1,000 employed adults. The poll found that nearly two-thirds (66%) of respondents had tried alcohol alternatives over the previous six months. Nearly a quarter (24%) said that they had 'at least partially' replaced alcohol with cannabis-infused or non-alcoholic beverages. Among millennials and Gen Zers, one in three said that they were opting for THC beverages over alcoholic drinks. 'To unwind after work, 45 percent drink alcohol, while 24 percent use nicotine, 20 percent turn to cannabis, and 16 percent choose alcohol alternatives like mocktails, non-alcoholic beer, or CBD,' the survey found. 'When it comes to winding down after a long day, Americans are reaching for a mix of familiar comforts and emerging alternatives,' Drug Rehab USA wrote in the Key Takeaways of the survey. 'While alcohol still dominates, the competition between nicotine and cannabis shows how habits are evolving across generations.' 'After-work rituals are no longer limited to a nightly drink—or even to alcohol at all. From THC-infused beverages to nicotine pouches and non-alcoholic alternatives, today's habits reflect a broader redefinition of what it means to unwind,' Drug Rehab USA noted. 'While motivations vary—stress, routine, social connection—the through-line is clear: Americans are turning to consumable rituals to draw a line between work and rest. For many, those rituals begin within the hour and recur multiple times a week.' Consumers Spend Billions On Weed Drinks Lambert Perkins, chief marketing officer at Triple Cannabis Beverages, says that the poll's results illustrate young adults' evolving views on alcohol. 'Gen Z is rewriting the rules of social drinking. They are mindful, intentional, and looking for experiences without the tradeoffs that come with alcohol,' Perkins writes in an emailed statement about the survey. 'Many still want the ritual of having a drink with friends, but they are over the hangover, the calories, and the bloat. Cannabis beverages give them the best of both worlds: something to sip on that is social, but with more control and fewer consequences.' 'We hear from consumers every week that they are swapping cannabis beverages into moments where alcohol used to be the default such as happy hours, concerts, and winding down at home,' he adds. The global cannabis beverage market is expected to reach $3.1 billion per year by 2030, according to a business data analysis report from Research and Markets published last month. Hemp-derived THC beverages are especially popular, both with manufacturers that avoid the red tape of regulated marijuana and customers who appreciate the accessibility of hemp products, which were legalized with the passage of the 2018 Farm Bill. Today, cannabis beverages can be found in many areas, with products including infused seltzers, malted brews and other drinks available in bottles, cans and on-tap available in most states.

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia
Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

Yahoo

time16 hours ago

  • Yahoo

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

REYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Patrik Ling has joined the company as VP Investor Relations Scandinavia, based in Stockholm. Patrik Ling has more than 25 years of experience in the life-science industry. Most recently he served as Senior Equity Analyst at the investment bank DNB Carnegie, covering life science companies, including Alvotech. He began his career in marketing and sales of pharmaceuticals, before transitioning to the financial sector, where he was a portfolio manager and equity analyst focusing on the life-science sector. 'It is a great pleasure to have Patrik on board, as he's been following Alvotech closely over the years and is a highly respected expert within the life science industry in Scandinavia. Patrik's background in both pharma and finance, will be a great asset to our team as we continue to broaden our shareholder base in Scandinavia and affirm Alvotech's role as a leading life science company in the Nordics,' said Róbert Wessman, chairman and CEO of Alvotech. 'This is a truly exciting time to join Alvotech, with its expanding portfolio of products in the market and in development, supported by a new base of R&D operations in Sweden. Biosimilars play an important role in meeting the growing demand for high-quality biologics and controlling the escalating cost of healthcare. I look forward to engaging with Scandinavian investors, helping them to better understand Alvotech's strengths and value proposition,' said Patrik Ling. About AlvotechAlvotech is a biotech company, founded by Róbert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy's (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Megalabs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit None of the information on the Alvotech website shall be deemed part of this press release. For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube. ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONSBenedikt Stefansson,

Iron Drugs Market Analysis and Outlook (2018-2030) by Drug Type, Indication, Distribution Channel, End User, Formulation and Region
Iron Drugs Market Analysis and Outlook (2018-2030) by Drug Type, Indication, Distribution Channel, End User, Formulation and Region

Yahoo

time17 hours ago

  • Yahoo

Iron Drugs Market Analysis and Outlook (2018-2030) by Drug Type, Indication, Distribution Channel, End User, Formulation and Region

Opportunities in the iron drugs market include developing next-gen formulations to address global anemia, innovating in precision medicine for improved delivery and adherence, and expanding manufacturing capabilities amid tariff challenges Iron Drugs Market Dublin, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The "Iron Drugs Market by Drug Type (Intravenous, Oral), Indication (Chronic Kidney Disease, Heavy Menstrual Bleeding, Iron Deficiency Anemia), Distribution Channel, End User, Formulation - Global Forecast 2025-2030" has been added to offering. The Iron Drugs Market has demonstrated significant growth, evolving from USD 2.84 billion in 2024 to an anticipated USD 4.16 billion by 2030, due to a compounded annual growth rate of 6.57%. This market research explores the dynamic landscape of iron-based therapeutics, shedding light on their critical role in combating anemia globally and driving innovation in healthcare. With millions impacted by iron deficiency, the demand for advanced iron drug therapies is on the rise, necessitating a concerted effort from healthcare systems and pharmaceutical developers to push the boundaries of current treatment paradigms. Innovations Driving the Iron Drugs Market The realm of iron drug development is witnessing transformative changes, fueled by advancements in formulation science and precision medicine. New delivery systems and polymer-stabilized complexes are circumventing traditional limitations. These innovations are pivotal in providing strategic planning insights for companies aiming to enhance competitive advantage by reducing oxidative stress and minimizing adverse reactions. With digital health platforms integrating into patient engagement, real-time monitoring of hemoglobin levels and adherence is now feasible, enabling more personalized treatment approaches. Supply Chain Impacts: 2025 U.S. Tariff Policies The revised United States tariff policies of 2025 have introduced new challenges in the iron drug supply chain. Companies are pressured to rethink procurement strategies due to increased import duties on raw materials. Manufacturers leverage dual-sourcing and domestic production to defuse these pressures, aligning operational strategies with risk mitigation and market entry benefits. These adjustments emphasize the need for resilient supply networks and underscore the importance of strategic partnerships and contractual innovations in maintaining supply continuity amid fluctuations. Key Takeaways from This Report Intravenous formulations dominate acute care settings, whereas oral iron supplements prevail in outpatient care. Strategic tailoring of iron therapies for specific indications such as chronic kidney disease and pregnancy-related anemia optimizes patient outcomes. E-commerce has a pivotal role in expanding the distribution of oral supplements. Dosing innovation, such as new formulation types, continues to improve therapeutic outcomes and patient satisfaction. Regional Market Dynamics Geographic differences in health frameworks and market access strategies are shaping iron drug adoption across global territories. In the Americas, comprehensive reimbursement mechanisms enhance the adoption of intravenous formulations. Europe, the Middle East, and Africa exhibit diverse regulatory landscapes that necessitate tailored approaches. In Asia-Pacific, demographic shifts and infrastructure expansion broaden the scope for cost-effective therapies, presenting competitive threats and opportunities for market expansion strategies. Competitive Landscape and Strategic Initiatives Key players such as Vifor Pharma and Fresenius Kabi are driving growth through strategic alliances and technological advancements. Mid-sized innovators carve niche markets by enhancing oral absorption regimens. Collaborations among contract research organizations and pharmaceutical companies are expediting clinical validation. These strategies are essential for maintaining a competitive edge, fostering portfolio diversification, and ensuring sustainable market growth. Key Attributes Report Attribute Details No. of Pages 194 Forecast Period 2025-2030 Estimated Market Value (USD) in 2025 $3.03 Billion Forecasted Market Value (USD) by 2030 $4.16 Billion Compound Annual Growth Rate 6.5% Regions Covered Global Key Topics Covered1. Preface1.1. Objectives of the Study1.2. Market Segmentation & Coverage1.3. Years Considered for the Study1.4. Currency & Pricing1.5. Language1.6. Stakeholders2. Research Methodology2.1. Define: Research Objective2.2. Determine: Research Design2.3. Prepare: Research Instrument2.4. Collect: Data Source2.5. Analyze: Data Interpretation2.6. Formulate: Data Verification2.7. Publish: Research Report2.8. Repeat: Report Update3. Executive Summary4. Market Overview4.1. Introduction4.2. Market Sizing & Forecasting5. Market Dynamics5.1. Growing adoption of ferric carboxymaltose infusions for chronic anemia management in nephrology settings5.2. Advancements in oral heme iron supplements boosting bioavailability for pregnant women5.3. Integration of digital adherence monitoring tools to improve compliance in iron therapy regimens5.4. Emergence of plant-based chelated iron formulations targeting vegetarian and vegan consumer segments5.5. Regulatory pathways accelerating approval of generic intravenous iron complex drugs in emerging markets5.6. Pharmacoeconomic evaluations highlighting cost savings of long-acting iron dextran versus traditional formulations5.7. Development of nanoparticle iron delivery platforms to reduce gastrointestinal side effects in patients5.8. Strategic partnerships between biotech firms and hospitals to pilot iron replacement infusion centers5.9. Influence of global anemia screening initiatives on demand for point-of-care iron testing and therapies5.10. Impact of rising inflammatory bowel disease prevalence on specialized iron supplementation protocols6. Market Insights6.1. Porter's Five Forces Analysis6.2. PESTLE Analysis7. Cumulative Impact of United States Tariffs 20258. Iron Drugs Market, by Drug Type8.1. Introduction8.2. Intravenous8.2.1. Ferric Carboxymaltose8.2.2. Ferric Gluconate8.2.3. Iron Dextran8.2.4. Iron Sucrose8.3. Oral8.3.1. Ferrous Fumarate8.3.2. Ferrous Gluconate8.3.3. Ferrous Sulfate8.3.4. Polysaccharide Iron Complex9. Iron Drugs Market, by Indication9.1. Introduction9.2. Chronic Kidney Disease9.3. Heavy Menstrual Bleeding9.4. Iron Deficiency Anemia9.5. Pregnancy Related Anemia10. Iron Drugs Market, by Distribution Channel10.1. Introduction10.2. Clinics10.3. Hospital Pharmacies10.4. Online Pharmacies10.5. Retail Pharmacies11. Iron Drugs Market, by End User11.1. Introduction11.2. Ambulatory Care Centers11.3. Clinics11.4. Home Care11.5. Hospitals12. Iron Drugs Market, by Formulation12.1. Introduction12.2. Capsules12.3. Effervescent12.4. Injectable12.5. Liquid12.6. Tablets13. Americas Iron Drugs Market13.1. Introduction13.2. United States13.3. Canada13.4. Mexico13.5. Brazil13.6. Argentina14. Europe, Middle East & Africa Iron Drugs Market14.1. Introduction14.2. United Kingdom14.3. Germany14.4. France14.5. Russia14.6. Italy14.7. Spain14.8. United Arab Emirates14.9. Saudi Arabia14.10. South Africa14.11. Denmark14.12. Netherlands14.13. Qatar14.14. Finland14.15. Sweden14.16. Nigeria14.17. Egypt14.18. Turkey14.19. Israel14.20. Norway14.21. Poland14.22. Switzerland15. Asia-Pacific Iron Drugs Market15.1. Introduction15.2. China15.3. India15.4. Japan15.5. Australia15.6. South Korea15.7. Indonesia15.8. Thailand15.9. Philippines15.10. Malaysia15.11. Singapore15.12. Vietnam15.13. Taiwan16. Competitive Landscape16.1. Market Share Analysis, 202416.2. FPNV Positioning Matrix, 202416.3. Competitive AnalysisThe major companies profiled in this Iron Drugs market report include: Vifor Pharma AG Covis Pharma Holding B.V. Pharmacosmos A/S Fresenius Kabi AG Baxter International Inc. Takeda Pharmaceutical Company Limited American Regent, Inc. B. Braun Melsungen AG Citius Pharmaceuticals, Inc. Teva Pharmaceutical Industries Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Iron Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store